Portfolio Companies News
November 22, 2017First patients enter TARGET study, ...
Toulouse, FRANCE, Lakeland, UNITED STATES, November 22, 2017, 8.00 am CET – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible) an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and... read more
November 22, 2017Nordic Nanovector Capital Markets D...
22.11.2017 07:24 Nordic Nanovector ASA (OSE: NANO) hosts its Capital Markets Day (CMD) today in Oslo. Oslo, Norway, 22 November 2017 The presentations will be held by members of the executive management team as well as selected external expert speakers, including Prof. Pier Luigi ... read more
November 22, 2017Nordic Nanovector ASA - Results for...
22.11.2017 07:03 Oslo, Norway, 22 November 2017 Nordic Nanovector ASA (OSE: NANO) announces results for the third quarter 2017. A presentation by the company’s senior management team will take place today following the company’s Capital Markets Day in Oslo (see separate announcemen... read more
November 20, 2017Zubsolv® receives authorization fo...
Uppsala, Sweden – November 20, 2017 – Orexo AB (publ.) today announce that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating treatment option for opioid dependence. Zubsolv, is a sublingual t... read more
November 16, 2017Wilson Therapeutics to host confere...
Nov 16, 2017 On November 23, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the third quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 10:00 CET. The eve... read more
November 13, 2017Q3 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 109 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
24 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.